September's Perfect Stocks (Use Caution) | Stryker Remains A Solid Long-Term Investment

[] We like to start the quarter with new stocks and new opportunities to make money, so Garrett has provided a list of great stocks to trade ahead of earnings season. [View in browser]( . We like to start the quarter with new stocks and new opportunities to make money, so Garrett has provided a list of great stocks to trade ahead of earnings season. [View in browser]( . . [] [Havens Investment Letter] [] [Havens Investment Letter] [] [] [] CBOE Veteran: “The Biggest Breakthrough of My Career” Why is CBOE veteran and legendary trader Alan Knuckman so excited? Because the breakthrough “50 Cent Gamma Trades” are a game changer... even for him! And now, he's set to reveal the details to you so you can learn how he spots these trades. [Sign up here to learn Alan's system]( [] --------------------------------------------------------------- [] CBOE Veteran: “The Biggest Breakthrough of My Career” Why is CBOE veteran and legendary trader Alan Knuckman so excited? Because the breakthrough “50 Cent Gamma Trades” are a game changer... even for him! And now, he's set to reveal the details to you so you can learn how he spots these trades. [Sign up here to learn Alan's system]( [] --------------------------------------------------------------- [] [] Stryker Remains A Solid Long-Term Investment [Bauer Pic] Dear Investor, Are you also increasingly looking for crisis-resistant stocks in these stormy stock market times? The medical sector is a good choice in this respect. In addition to the classic pharmaceutical crisis winners, selected medical technology stocks also offer you a fairly high degree of security. Today I would like to show you a sector stock that is suitable as a long-term investment for conservative investors: the US company Stryker (SYK). Brief Portrait The US medical technology group produces high-tech implants for oral and maxillofacial surgery as well as artificial knee, hip and shoulder joints. In addition, Stryker offers surgical technology, surgical robots, trauma systems and endoscopy systems. Accessories and consumables for patient care, as well as products for trauma care such as stretchers, round out the product range. New Record Figures After The Corona Dent Stryker is a prime example of consistency: year after year, the company manages to increase sales and profits. The Corona pandemic caused a brief interruption in this series. In numerous clinics, non-essential operations had to be postponed. But postponed is not canceled. When the situation in the clinics returned to normal, the operations were made up for. This can be seen wonderfully in the numbers: While Stryker's sales in 2020 were slightly lower than in 2019, the company benefited from the corresponding catch-up effects in 2021 and made a significant leap to new record figures for sales and profits. For the current year as well as for 2023, analysts expect a normalization and forecast a return to the usual growth rates in the high single-digit percentage range for sales and profit. Whereby the growth rate for earnings per share is also likely to be in the double-digit percentage range in some cases. Solid Business In Q2 The most recently reported second quarter results were in line with expectations. Stryker reported a +5% increase in revenue to $4.49 billion. Earnings per share of $2.25 were exactly the same as in the same period last year. The strong US dollar had a negative impact on international business. Without the negative exchange rate effect, growth rates would have been a few percentage points higher. But this is a short-term factor that can quickly turn around. High Resistance To Crisis Unlike the Corona pandemic, a recession cannot do much to Stryker's business. Even when cash is tight, operations enjoy top priority. Nevertheless, Stryker's stock has been dragged down by the general market weakness. Currently, the price-to-earnings (P/E) ratio is 21, but it will drop to 19 next year thanks to rising profits. This is significantly below the historical average of around 25. For long-term investors, it is therefore definitely worth taking a closer look at the stock. Conservative investors will also appreciate the high consistency of the share price performance. For more than a decade, the share price has been rising without any major setbacks (apart from the Corona crash in spring 2020). Best regards, [Bauer signature] Dr. Gregor Bauer Chief Analyst, European Markets [] --------------------------------------------------------------- [] [] Stryker Remains A Solid Long-Term Investment [Bauer Pic] Dear Investor, Are you also increasingly looking for crisis-resistant stocks in these stormy stock market times? The medical sector is a good choice in this respect. In addition to the classic pharmaceutical crisis winners, selected medical technology stocks also offer you a fairly high degree of security. Today I would like to show you a sector stock that is suitable as a long-term investment for conservative investors: the US company Stryker (SYK). Brief Portrait The US medical technology group produces high-tech implants for oral and maxillofacial surgery as well as artificial knee, hip and shoulder joints. In addition, Stryker offers surgical technology, surgical robots, trauma systems and endoscopy systems. Accessories and consumables for patient care, as well as products for trauma care such as stretchers, round out the product range. New Record Figures After The Corona Dent Stryker is a prime example of consistency: year after year, the company manages to increase sales and profits. The Corona pandemic caused a brief interruption in this series. In numerous clinics, non-essential operations had to be postponed. But postponed is not canceled. When the situation in the clinics returned to normal, the operations were made up for. This can be seen wonderfully in the numbers: While Stryker's sales in 2020 were slightly lower than in 2019, the company benefited from the corresponding catch-up effects in 2021 and made a significant leap to new record figures for sales and profits. For the current year as well as for 2023, analysts expect a normalization and forecast a return to the usual growth rates in the high single-digit percentage range for sales and profit. Whereby the growth rate for earnings per share is also likely to be in the double-digit percentage range in some cases. Solid Business In Q2 The most recently reported second quarter results were in line with expectations. Stryker reported a +5% increase in revenue to $4.49 billion. Earnings per share of $2.25 were exactly the same as in the same period last year. The strong US dollar had a negative impact on international business. Without the negative exchange rate effect, growth rates would have been a few percentage points higher. But this is a short-term factor that can quickly turn around. High Resistance To Crisis Unlike the Corona pandemic, a recession cannot do much to Stryker's business. Even when cash is tight, operations enjoy top priority. Nevertheless, Stryker's stock has been dragged down by the general market weakness. Currently, the price-to-earnings (P/E) ratio is 21, but it will drop to 19 next year thanks to rising profits. This is significantly below the historical average of around 25. For long-term investors, it is therefore definitely worth taking a closer look at the stock. Conservative investors will also appreciate the high consistency of the share price performance. For more than a decade, the share price has been rising without any major setbacks (apart from the Corona crash in spring 2020). Best regards, [Bauer signature] Dr. Gregor Bauer Chief Analyst, European Markets --------------------------------------------------------------- [] Pick the Perfect Apple Trade -- with 70% Success Rate and a 3-to-1 Reward-to-Risk Ratio [apples in basket]( [Learn the method here]( --------------------------------------------------------------- [] [] Pick the Perfect Apple Trade -- with 70% Success Rate and a 3-to-1 Reward-to-Risk Ratio [apples in basket]( [Learn the method here]( --------------------------------------------------------------- [] [] [] September's Perfect Stocks [Garrett Pic] Market momentum is Yellow. The S&P 500 is fighting to maintain the 4,000 level, and the index has been strong despite low volume conditions. There is ample reason to speculate a bit, but there are other ways to profit over the long term. We talk about the top stocks with great balance sheets today. Dear Investor, How do we trade the best stocks? Cash secured puts and credit spreads offer you great potential as you dip a toe back into the market. If you’ve followed me over the last few weeks, I’ve written extensively about these trades and told you the momentum indicator after every single trading session. The stocks that I am discussing are ones built for long-term rebounds and breakouts. You can also position size into these stocks over the months ahead… I look at three different metrics to help build a list of winning low-risk and high-upside stocks, given their rock-solid balance sheets. This is the ultimate Do-It-Yourself lesson. Start right here: - The Piotroski F-score - The Altman Z-score - A valuation rank Here’s How It Works Let’s start by finding positive financial growth and low debt exposure. That’s where the Piotroski F-score succeeds. The F-score is a NINE-POINT system that rewards each company for meeting a certain criterion on its balance sheet. If the company meets all nine criteria, it has an F-score of 9. That means it’s perfect. The Altman Z-score is a weighted average of five metrics to determine whether a company might go out of business. If a company falls below 2.6, it has a risky balance sheet. That risk is tied to a balance sheet that likely has lots of debt or weak cash flow. We are looking for stocks with a Z-score of 3 or higher. This is pure forensic analysis. But let’s add one last element to this. We want our stocks to have attractive valuations. We don’t want to trade at 15 times sales or 30 times revenue. We don’t want to have negative book value or negative EBIT. So, we aim for stocks with attractive buyout values. I use EV/EBIT to allow us to have a proper “apples to oranges” comparison today. I’ll keep the number at roughly 7 or less. The List of Lists (For Month 9) Okay… Here are your top F and Z score stocks for September. [Perfect Stocks]( There are some beaten-up stocks on this list after our negative momentum switch back in late August. Now, there’s an opportunity in the next two weeks should momentum remain stronger. Think about trading (selling) out of the money puts here… Why deep out of the money? If the stocks go higher, you’ll make money. You’ll make money if the stocks don’t reach the strike price. And if the stock falls to the strike price, you’ll get a great stock at a much cheaper valuation than today. Remember, you’re picking a level where you’d be happy to buy the stock… It’s “win, win, win.” Enjoy your day, [Garrett signature] Garrett {NAME} Chief Analyst, American Markets [] --------------------------------------------------------------- [] [] September's Perfect Stocks [Garrett Pic] Market momentum is Yellow. The S&P 500 is fighting to maintain the 4,000 level, and the index has been strong despite low volume conditions. There is ample reason to speculate a bit, but there are other ways to profit over the long term. We talk about the top stocks with great balance sheets today. Dear Investor, How do we trade the best stocks? Cash secured puts and credit spreads offer you great potential as you dip a toe back into the market. If you’ve followed me over the last few weeks, I’ve written extensively about these trades and told you the momentum indicator after every single trading session. The stocks that I am discussing are ones built for long-term rebounds and breakouts. You can also position size into these stocks over the months ahead… I look at three different metrics to help build a list of winning low-risk and high-upside stocks, given their rock-solid balance sheets. This is the ultimate Do-It-Yourself lesson. Start right here: - The Piotroski F-score - The Altman Z-score - A valuation rank Here’s How It Works Let’s start by finding positive financial growth and low debt exposure. That’s where the Piotroski F-score succeeds. The F-score is a NINE-POINT system that rewards each company for meeting a certain criterion on its balance sheet. If the company meets all nine criteria, it has an F-score of 9. That means it’s perfect. The Altman Z-score is a weighted average of five metrics to determine whether a company might go out of business. If a company falls below 2.6, it has a risky balance sheet. That risk is tied to a balance sheet that likely has lots of debt or weak cash flow. We are looking for stocks with a Z-score of 3 or higher. This is pure forensic analysis. But let’s add one last element to this. We want our stocks to have attractive valuations. We don’t want to trade at 15 times sales or 30 times revenue. We don’t want to have negative book value or negative EBIT. So, we aim for stocks with attractive buyout values. I use EV/EBIT to allow us to have a proper “apples to oranges” comparison today. I’ll keep the number at roughly 7 or less. The List of Lists (For Month 9) Okay… Here are your top F and Z score stocks for September. [Perfect Stocks]( There are some beaten-up stocks on this list after our negative momentum switch back in late August. Now, there’s an opportunity in the next two weeks should momentum remain stronger. Think about trading (selling) out of the money puts here… Why deep out of the money? If the stocks go higher, you’ll make money. You’ll make money if the stocks don’t reach the strike price. And if the stock falls to the strike price, you’ll get a great stock at a much cheaper valuation than today. Remember, you’re picking a level where you’d be happy to buy the stock… It’s “win, win, win.” Enjoy your day, [Garrett signature] Garrett {NAME} Chief Analyst, American Markets --------------------------------------------------------------- [] [] Now Available: The Brainchild of Wall Street Mavericks — the Perfect Apple Trade If you ever thought that it’s way too late to see significant movement in major stocks like AAPL... You need to think again… The Perfect Apple Trade Has Been Discovered Thanks to the help of a maverick group of former Wall Street traders… and a state-of-the-art artificial intelligence platform… California tech wiz and renowned trader Micah Lamar has uncovered obscure “trade cycles” in AAPL shares capable of signaling major movement… All in a matter of days... These Aren’t Common Results Nearly all market analysts are clueless about these moves… But Micah’s proprietary system has been able to predict significant moves in AAPL stock… over and over again. Now, You Can See the System for Yourself! He’ll walk you through his AAPL system step-by-step… and answer the most common questions he sees... You’ll even be able to gain access to Micah’s proprietary Apple trading tool… Plus, you’ll see the remarkable results Micah’s system has returned, just by placing one trade on iconic Apple Inc., the crown jewel of tech stocks… [Click here to gain immediate access to this presentation]( You’ll be one of the lucky few to see the Perfect Apple Trade system yourself… And meet the brilliant inventor behind this system… [Catch it all here]( --------------------------------------------------------------- [] [] [] Now Available: The Brainchild of Wall Street Mavericks — the Perfect Apple Trade If you ever thought that it’s way too late to see significant movement in major stocks like AAPL... You need to think again… The Perfect Apple Trade Has Been Discovered Thanks to the help of a maverick group of former Wall Street traders… and a state-of-the-art artificial intelligence platform… California tech wiz and renowned trader Micah Lamar has uncovered obscure “trade cycles” in AAPL shares capable of signaling major movement… All in a matter of days... These Aren’t Common Results Nearly all market analysts are clueless about these moves… But Micah’s proprietary system has been able to predict significant moves in AAPL stock… over and over again. Now, You Can See the System for Yourself! He’ll walk you through his AAPL system step-by-step… and answer the most common questions he sees... You’ll even be able to gain access to Micah’s proprietary Apple trading tool… Plus, you’ll see the remarkable results Micah’s system has returned, just by placing one trade on iconic Apple Inc., the crown jewel of tech stocks… [Click here to gain immediate access to this presentation]( You’ll be one of the lucky few to see the Perfect Apple Trade system yourself… And meet the brilliant inventor behind this system… [Catch it all here]( --------------------------------------------------------------- [] [] Article Recap - [Stryker Remains A Solid Long-Term Investment](#i572731) - [September's Perfect Stocks](#i572028) - [Now Available: The Brainchild of Wall Street Mavericks — the Perfect Apple Trade](#156381) --------------------------------------------------------------- [] Article Recap - [Stryker Remains A Solid Long-Term Investment](#i572731) - [September's Perfect Stocks](#i572028) - [Now Available: The Brainchild of Wall Street Mavericks — the Perfect Apple Trade](#156381) --------------------------------------------------------------- [] © 2022 Godesburg Financial Publishing, Inc. DISCLAIMER: COMMUNICATIONS FROM GODESBURG FINANCIAL PUBLISHING (GFP) ARE FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY – NOT INVESTMENT ADVICE: GFP and all the services it offers are for educational and informational purposes only and should NOT be understood to be securities-related offers or solicitations. None of GFP’s communications should be considered or used as personalized investment advice. GFP recommends that you speak with a licensed professional before making any investment decision. RESULTS PRESENTED ARE NOT NECCESSARILY TYPICAL OR VERIFIED: GFP communications may include information regarding the historical trading performance of gurus in their services (all verified by a third party), as well as testimonials of non-employees depicting profitable investments and trades that are believed to be true based on the representations of the persons providing the testimonial of their own free will. Please be aware that the claims regarding investing or trading results of non-employees are not tracked by GFP nor can they be verified. As always, past performance is not necessarily indicative of future results. Therefore, results presented in this email should NOT be considered TYPICAL. Actual results can and will vary based on everything from experience, ability, risk mitigation practices, and market volatility... to the amount of money exposed in the investment or trade. Investing and trading are speculative and carry serious risk. You may lose some, all - or possibly more - than your original investment or trade. GODESBURG FINANCIAL PUBLISHING IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER: GFP, including its owners and employees, are NOT registered as securities broker-dealers, brokers, or any sort of registered investment advisors with the U.S. Securities and Exchange Commission, any state securities regulatory authorities, or any self-regulatory organizations. GODESBURG FINANCIAL PUBLISHING EMPLOYEES MAY HOLD SECURITIES DISCUSSED: If a writer holds any securities in a communication, it will be disclosed along with the information on the potential investment or trade. HIR, its owners or employees, have not been - or ever will be - paid by the issuer of a security mentioned in our services or communications. GFP, its owners and employees are paid entirely or in part from commissions based on sales of their services to subscribers. For more information, please visit [our disclaimer page here.]( Sent to: {EMAIL} [Unsubscribe]( Godesburg Financial Publishing Inc., 251 Little Falls Drive, Wilmington, DE 19808, United States [] © 2022 Godesburg Financial Publishing, Inc. DISCLAIMER: COMMUNICATIONS FROM GODESBURG FINANCIAL PUBLISHING (GFP) ARE FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY – NOT INVESTMENT ADVICE: GFP and all the services it offers are for educational and informational purposes only and should NOT be understood to be securities-related offers or solicitations. None of GFP’s communications should be considered or used as personalized investment advice. GFP recommends that you speak with a licensed professional before making any investment decision. RESULTS PRESENTED ARE NOT NECCESSARILY TYPICAL OR VERIFIED: GFP communications may include information regarding the historical trading performance of gurus in their services (all verified by a third party), as well as testimonials of non-employees depicting profitable investments and trades that are believed to be true based on the representations of the persons providing the testimonial of their own free will. Please be aware that the claims regarding investing or trading results of non-employees are not tracked by GFP nor can they be verified. As always, past performance is not necessarily indicative of future results. Therefore, results presented in this email should NOT be considered TYPICAL. Actual results can and will vary based on everything from experience, ability, risk mitigation practices, and market volatility... to the amount of money exposed in the investment or trade. Investing and trading are speculative and carry serious risk. You may lose some, all - or possibly more - than your original investment or trade. GODESBURG FINANCIAL PUBLISHING IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER: GFP, including its owners and employees, are NOT registered as securities broker-dealers, brokers, or any sort of registered investment advisors with the U.S. Securities and Exchange Commission, any state securities regulatory authorities, or any self-regulatory organizations. GODESBURG FINANCIAL PUBLISHING EMPLOYEES MAY HOLD SECURITIES DISCUSSED: If a writer holds any securities in a communication, it will be disclosed along with the information on the potential investment or trade. HIR, its owners or employees, have not been - or ever will be - paid by the issuer of a security mentioned in our services or communications. GFP, its owners and employees are paid entirely or in part from commissions based on sales of their services to subscribers. For more information, please visit [our disclaimer page here.]( Sent to: {EMAIL} [Unsubscribe]( Godesburg Financial Publishing Inc., 251 Little Falls Drive, Wilmington, DE 19808, United States